10-K: Earth Science Tech Inc. Reports Strong Revenue Growth and Net Profit in Fiscal Year 2024

Earth Science Tech, Inc. reports a significant increase in revenue and a shift to net profit for the fiscal year ending March 31, 2024, driven by its compounding pharmacy and telemedicine operations.

Summary

• Earth Science Tech, Inc. (ETST) reported a substantial increase in revenue to $11,953,635 for the fiscal year ended March 31, 2024, compared to $48,537 in the previous year.
• The company achieved a gross profit of $7,828,496, representing a gross margin of 65%, a significant improvement from the 45% gross margin in the previous year.
• ETST recorded a net income of approximately $812,000 for the fiscal year 2024, a turnaround from a net loss of approximately $365,000 in the previous fiscal year.
• The company's revenue growth is attributed to an aggressive marketing campaign, the operation of a newly built sterile compounding room, and proprietary IT systems.
• Operating expenses increased significantly, primarily due to increased labor costs, legal and professional fees, and bank charges related to higher sales volume.
• The company's cash position improved significantly, with cash on hand increasing from $35,756 to $697,721.
• ETST repurchased 5,200,000 shares of its common stock for $178,000 during the fiscal year.

Sentiment

Score: 8

Explanation: The document shows a strong positive trend with significant revenue growth and a shift to profitability. However, there are some concerns about increasing operating expenses and the effectiveness of internal controls.

Positives

• The company has successfully transitioned from a net loss to a net profit.
• The company has significantly increased its revenue and gross profit.
• The company has improved its cash position.
• The company has expanded its operational capabilities with the approval of its sterile compounding room.
• The company has a strong gross margin of 65%.

Negatives

• Operating expenses increased significantly, primarily due to increased labor costs, legal and professional fees, and bank charges.
• The company's disclosure controls and procedures were deemed ineffective as of March 31, 2024.
• The company has a history of net losses and a significant accumulated deficit.

Risks

• The company operates in a highly competitive market.
• The company is subject to complex healthcare laws and regulations.
• The company's business is subject to risks related to cybersecurity and data breaches.
• The company may require additional capital in the future for acquisitions.
• The company's stock is traded on the OTC Pink Market, which may have an unfavorable impact on its stock price and liquidity.
• The company's Series B class Preferred stock structure concentrates voting power with the CEO.

Future Outlook

The company does not anticipate needing any future financing unless it undertakes an acquisition. The company intends to expand offerings to include over the counter (OTC) (non-prescription) products such as supplements and topicals.

Management Comments

• The revenue increase in the year ended on March 31, 2024, compared with the year ended on March 31, 2023, is primarily due to an aggressive marketing campaign and compounding products in the newly built sterile room, combined with proprietary IT that facilitates clinicians in sending prescriptions to be fulfilled and tracks shipping in real time.
• Gross Margin increase is driven by the Company’s subsidiaries increased buying power, which provides the ability to negotiate better prices on raw active ingredient products.

Industry Context

The company operates in the growing telehealth and compounding pharmaceutical sectors, which are experiencing significant structural change and consolidation. The company faces competition from other specialty compounding pharmacies and telehealth platforms.

Comparison to Industry Standards

• The company's gross margin of 65% is relatively high compared to some traditional pharmaceutical providers, but is in line with other specialty compounding pharmacies.
• The company's revenue growth is significantly higher than the average growth rate in the pharmaceutical industry, indicating a strong market position.
• The company's transition to net profit is a positive sign, as many smaller pharmaceutical companies struggle to achieve profitability in their early stages.
• The company's reliance on a few large customers may pose a risk, as the loss of one or more of these customers could significantly impact revenue.

Management Changes

Corporate Governance

Legal Proceedings

• The company settled a complaint with the AMF (Quebec Securities Regulator) by paying a fine of $10,000 CAD and agreeing not to sell any securities in Quebec.
• One of the company's subsidiaries, RxCompoundStore.Com, LLC, was sued in Federal court by Eli Lilly, but the case was dismissed with prejudice on April 10, 2024.

Related Party Transactions

• The company pays the employee compensation for Giorgio R. Saumat and Mario Tabraue to their respective, solely owned LLCs, Point96 Consulting, LLC and Tabraue Consulting, LLC.
• Officer compensation totaling $3,611,594 was incurred during the year, paid to Point 96 Consultant owned by Giorgio R. Saumat and Tabraue Consulting, owned by Mario Tabraue.
• The Company reimbursed Point 96 Consultant for marketing and SG&A in the amount of $428,000.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and transition to profitability.
• Employees may benefit from increased job security and potential for future growth.
• Customers will benefit from the company's expanded offerings and improved services.
• Creditors may benefit from the company's improved financial stability.

Next Steps

• The company intends to expand offerings to include over the counter (OTC) (non-prescription) products such as supplements and topicals.
• The company will continue to improve its internal controls.

Key Dates

Keywords

pharmaceuticals, telemedicine, compounding pharmacy, healthcare, revenue growth, net profit, OTC Pink Market, financial results, prescription fulfillment, health and wellness